TTR and familial amyloid neuropathy: Thus, pioneering clinical studies include RNAi drugs targeting liver synthesis of PCSK9, resulting in highly significant lowering of LDL cholesterol or targeting liver transthyretin (TTR) synthesis for treatment of cardiac TTR amyloidosis.